Literature DB >> 6145357

Dissimilar dosing with high-potency and low-potency neuroleptics.

R J Baldessarini, B Katz, P Cotton.   

Abstract

The authors studied high-potency versus low-potency neuroleptic dosing practices for 110 Boston-area psychiatric inpatients and compared the findings with the dosing practices reported in surveys of nearly 16,000 Veterans Administration patients. Mean chlorpromazine equivalent doses for the most common agents correlated strongly in both samples. Although frequencies of lower doses of both types of agents were similar, doses of potent drugs above the daily equivalent of 1 g of chlorpromazine accounted for more than 40% of prescriptions. The mean chlorpromazine-equivalent dose of popular potent agents (haloperidol or fluphenazine) was 3.54 times as high as that of popular low-potency agents (chlorpromazine or thioridazine). Potent agents are commonly used in mania and schizophrenia, often in relatively high doses, which may carry an excess of risk over unproven added benefit.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145357     DOI: 10.1176/ajp.141.6.748

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  11 in total

1.  Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services.

Authors:  S P Segal; J R Bola; M A Watson
Journal:  Psychiatr Serv       Date:  1996-03       Impact factor: 3.084

2.  Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.

Authors:  R A Kiivet; A Llerena; M L Dahl; L Rootslane; J Sánchez Vega; T Eklundh; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

Review 3.  Antipsychotic dosing: found in translation.

Authors:  Gary Remington; Gagan Fervaha; George Foussias; Ofer Agid; Peter Turrone
Journal:  J Psychiatry Neurosci       Date:  2014-07       Impact factor: 6.186

Review 4.  Conventional versus novel antipsychotics: changing concepts and clinical implications.

Authors:  G Remington; S A Chong
Journal:  J Psychiatry Neurosci       Date:  1999-11       Impact factor: 6.186

5.  The feasibility of using automated data to assess guideline-concordant care for schizophrenia.

Authors:  T J Hudson; R R Owen; A E Lancaster; L Mason
Journal:  J Med Syst       Date:  1999-08       Impact factor: 4.460

6.  Neuroleptic medication and prescription practices with sheltered-care residents: a 12-year perspective.

Authors:  S P Segal; D Cohen; S R Marder
Journal:  Am J Public Health       Date:  1992-06       Impact factor: 9.308

7.  Clinical and demographic characteristics of chronic inpatients: implication for treatment and research.

Authors:  J W Barber; R Kerler; E J Kellogg; L S Godleski; J L Glick; P L Hundley; W V Vieweg
Journal:  Psychiatr Q       Date:  1988

8.  Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol.

Authors:  Sean Hennessy; Warren B Bilker; Jill S Knauss; Stephen E Kimmel; David J Margolis; Mary F Morrison; Robert F Reynolds; Dale B Glasser; Brian L Strom
Journal:  Br J Clin Pharmacol       Date:  2004-07       Impact factor: 4.335

9.  Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study.

Authors:  Ramin Mojtabai; Laura Fochtmann; Su-Wei Chang; Roman Kotov; Thomas J Craig; Evelyn Bromet
Journal:  Schizophr Bull       Date:  2009-06-08       Impact factor: 9.306

10.  Prolonged antidopaminergic actions of single doses of butyrophenones in the rat.

Authors:  A Campbell; R J Baldessarini; M H Teicher; N S Kula
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.